We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Basic research and clinical advances in squamous cell carcinoma of the head and neck.
- Authors
Wei Shang; Hai-jun Lu; Wei Li; Jia-wei Zheng
- Abstract
Squamous cell carcinoma of the head and neck (SCCHN) has been estimated to account for approximately 6%-7% of all malignancies, with more than 500 thousands newly diagnosed cases of SCCHN worldwide each year. Tobacco, alcohol and HPV are the most important causative factors in the development of oropharyngeal cancer. Cetuximab, an anti-EGFR monoclonal antibody, is able to inhibit phosphorylation of EGFR and to prevent signal transduction of EGFR so as to be a prominent target agent and treatment approach for SCCHN. Docetaxel, cisplatin, and fluorouracil are primarily administered concurrently with intensity modulated radiation therapy with the accelerated or hyperfractionated treatment for stage III or IV, locally advanced oropharyngeal, hypopharyngeal and laryngeal cancer. Although phase 3 trials involving patients with advanced SCCHN are ongoing, cetuximab has been promising both as single agent and in combination with radiotherapy as a postoperative adjuvant treatment for SCCHN.
- Subjects
SQUAMOUS cell carcinoma; EPIDERMAL growth factor; PAPILLOMAVIRUSES; DRUG therapy; RADIOTHERAPY; CETUXIMAB; FACE cancer; CANCER treatment
- Publication
China Journal of Oral & Maxillofacial Surgery, 2009, Vol 7, Issue 4, p290
- ISSN
1672-3244
- Publication type
Article